Catch and release to continue for 2019 Atlantic salmon recreational fishery in the Gulf Region

Apr 16, 2019

Moncton, New Brunswick - Atlantic salmon is a species of social, cultural and ceremonial importance throughout Atlantic Canada and beyond. Fisheries and Oceans Canada (DFO) announced today that mandatory catch and release management measures for the Atlantic salmon recreational fishery remains in place for 2019 in the rivers draining into the southern Gulf of St. Lawrence

The decline of Atlantic salmon is a serious concern and continues to be the subject of significant research. DFO continues to invest in science while working with Indigenous groups, our partners, and those involved in recreational fisheries to offer sustainable solutions for Atlantic salmon in the southern Gulf of St. Lawrence.

Management measures for the 2019 recreational fisheries in the Gulf region are informed by science advice, input from the recreational fisheries advisory committee, along with results from an annual online public consultation.

DFO remains committed to better understanding this species with the goal of protecting Atlantic salmon now and for future generations.

Source : Government Of Canada

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.